[Cilengitide: a new weapon against glioblastoma?].
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D017326:Clinical Trials, Phase III as Topic; D018572:Disease-Free Survival; D005060:Europe; D005909:Glioblastoma / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D015337:Multicenter Studies as Topic; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012910:Snake Venoms / Q000009:adverse effects / Q000627:therapeutic use*; D015996:Survival Rate
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D012910:Snake Venoms; C422910:Cilengitide